IPO registrations (S-1, F-1) · Registrants
RECURSION PHARMACEUTICALS, INC.
- SEC CIK
- 1601830 · filings on EDGAR ↗
- Former names
- Recursion Pharmaceuticals, LLC (2014–2015)
- Registration
- Form S-1, first filed 2021-03-22, last 2021-04-15; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2021-04-16; declared effective 2021-04-15
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 41S RIO GRANDE STREET, Salt Lake City, UT 84101
- EIN
- 46-4099738
- Ticker
- RXRX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- RECURSION PHARMACEUTICALS, INC. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2021-04-15)
- Final price
- $18.00 per share, within the range (424B4 filed 2021-04-16, an initial public offering)
- Shares sold
- 24,242,424
- Gross proceeds
- $436,363,632 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RXRX
- Lead underwriters
- Goldman Sachs; J.P. Morgan
- Syndicate
- BofA Securities; Leerink Partners; Allen & Company; KeyBanc Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: RECURSION PHARMACEUTICALS, INC EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Recursion Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: RECURSION PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: RECURSION PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: RECURSION PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: RECURSION PHARMACEUTICALS INC. EXACT (EIN (EXACT))
- Federal award recipient: RECURSION PHARMACEUTICALS INC Fuzzy (name and state)
- Form D issuer: RECURSION PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
- SEC filer: RECURSION PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-03-22 | S-1 | S-1 (registration) | RECURSION PHARMACEUTICALS, INC. | 0001193125-21-089610 ↗ |
| 2021-04-12 | S-1/A | S-1/A (amendment) | RECURSION PHARMACEUTICALS, INC. | 0001193125-21-112364 ↗ |
| 2021-04-15 | S-1/A | S-1/A (amendment) | RECURSION PHARMACEUTICALS, INC. | 0001193125-21-117033 ↗ |
| 2021-04-15 | S-1MEF | S-1MEF (added securities) | RECURSION PHARMACEUTICALS, INC. | 0001193125-21-118178 ↗ |
| 2021-04-15 | EFFECT | EFFECT (declared effective) | RECURSION PHARMACEUTICALS, INC. | 9999999995-21-001450 ↗ |
| 2021-04-16 | 424B4 | 424B4 (final prospectus) | RECURSION PHARMACEUTICALS, INC. | 0001193125-21-119404 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-04-15 | S-1/A | registration statement | $16.00–$18.00 | $17.00 | 22,000,000 | $374,000,000 | Nasdaq RXRX | 6 | primary document; range, price sentence, shares headline, proceeds computed, cover names 6 | document ↗ |
| 2021-04-16 | 424B4 | final prospectus | $18.00 | 24,242,424 | $436,363,632 | Nasdaq RXRX | 6 | primary document; price sentence, shares headline, proceeds table, cover names 6 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bogue Zachary | Director,TenPercentOwner | 11 | 2021–2023 | ||
| Borgeson Blake | Director | 83 | 2021–2026 | ||
| Burrell Terry-Ann | Director | 16 | 2021–2024 | ||
| CHAVEZ R. MARTIN | Director | 17 | 2021–2024 | ||
| Dar Zavain | Director | 24 | 2021–2026 | ||
| Data Collective IV GP, LLC | TenPercentOwner | 2 | 2021 | ||
| Data Collective IV, L.P. | TenPercentOwner | 2 | 2021 | ||
| DCVC Opportunity Fund II GP, LLC | TenPercentOwner | 2 | 2021 | ||
| DCVC Opportunity Fund II, L.P. | TenPercentOwner | 2 | 2021 | ||
| DCVC V GP, LLC | TenPercentOwner | 2 | 2021 | ||
| DCVC V, L.P. | TenPercentOwner | 2 | 2021 | ||
| Doyle Ramona | Officer | Chief Medical Officer | 8 | 2021–2022 | |
| Gibson Christopher | Director; Director,Officer; Director,Officer,TenPercentOwner | Chief Executive Officer | 110 | 2021–2026 | |
| HERSHBERG ROBERT | Director | 11 | 2021–2026 | ||
| Larson Tina Marriott | Officer | President and COO | 43 | 2021–2024 | |
| Li Dean Y | Director | 33 | 2021–2026 | ||
| Lux Co-Invest Opportunities, L.P. | Other; TenPercentOwner | 3 | 2021 | ||
| Lux Co-Invest Partners, LLC | Other; TenPercentOwner | 3 | 2021 | ||
| Lux Venture Partners IV, LLC | Other; TenPercentOwner | 3 | 2021 | ||
| Lux Ventures IV, L.P. | Other; TenPercentOwner | 3 | 2021 | ||
| Mamoura Diversified Global Holding PJSC | TenPercentOwner | 20 | 2021–2023 | ||
| Mubadala Investment Co PJSC | TenPercentOwner | 20 | 2021–2023 | ||
| Ocko Matthew | TenPercentOwner | 2 | 2021 | ||
| Secora Michael | Officer | Chief Financial Officer | 32 | 2021–2024 | |
| Virani Shafique | Officer | Chief Business Officer; Chief Corp. Dev. Officer | 24 | 2021–2024 | |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | Other; TenPercentOwner | 3 | 2021 | ||
| MIC Capital Management UK LLP | TenPercentOwner | 1 | 2021 | ||
| MIC Capital Partners (Public) Parallel Cayman, LP | TenPercentOwner | 1 | 2021 | ||
| Hebert Peter | Other | 1 | 2021 | ||
| Wolfe Josh | Other | 1 | 2021 | ||
| Mauro David J | Officer | Chief Medical Officer | 6 | 2023–2024 | |
| Khan Najat | Director; Director,Officer | CEO and President; Chief R&D Commercial Officer | 15 | 2024–2026 | |
| Michor Franziska | Director | 4 | 2024–2026 | ||
| Taylor Ben R | Officer | Chief Financial Officer | 23 | 2024–2026 | |
| Bumpus Namandje | Director | 5 | 2025–2026 | ||
| Sun Elaine D | Director | 4 | 2025–2026 | ||
| Hallett David | Officer | Chief Scientific Officer; CSO | 5 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-09-15 | RECURSION PHARMACEUTICALS, INC. | Pharmaceuticals | $245,896,677 | $245,896,677 | 49 | 2 |
| 2019-08-13 | RECURSION PHARMACEUTICALS, INC. | Pharmaceuticals | $122,057,689 | $122,057,689 | 33 | 1 |
| 2017-10-06 | RECURSION PHARMACEUTICALS, INC. | Pharmaceuticals | $59,999,975 | $55,799,946 | 26 | 1 |
| 2016-09-14 | RECURSION PHARMACEUTICALS, INC. | Pharmaceuticals | $15,034,984 | $15,034,984 | 18 | 2 |
| 2016-09-14 | RECURSION PHARMACEUTICALS, INC. | Pharmaceuticals | $32,000,000 | $32,000,000 | 32 | 1 |
| 2016-09-14 | RECURSION PHARMACEUTICALS, INC. | Pharmaceuticals | $4,066,996 | $4,066,996 | 31 | 1 |
| 2015-12-04 | Recursion Pharmaceuticals, LLC | Biotechnology | $2,700,000 | $2,650,000 | 8 | 1 |
| 2015-02-23 | Recursion Pharmaceuticals, LLC | Biotechnology | $1,000,000 | $830,000 | 19 | 1 |
| 2014-04-02 | Recursion Pharmaceuticals, LLC | Pharmaceuticals | $200,000 | $80,000 | 5 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Recursion Pharmaceuticals, Inc. | UT | State business registries | name and state |
| Business registration | RECURSION PHARMACEUTICALS, INC | UT | State business registries | name and state |
| Business registration | RECURSION PHARMACEUTICALS, INC. | UT | State business registries | name and state |
| Business registration | RECURSION PHARMACEUTICALS, INC. | UT | State business registries | name and state |
| Business registration | RECURSION PHARMACEUTICALS, INC. | UT | State business registries | name and state |
| Plan sponsor | RECURSION PHARMACEUTICALS INC. | UT | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | RECURSION PHARMACEUTICALS INC | UT | Federal spending (USAspending) | name and state |
| Form D issuer | RECURSION PHARMACEUTICALS, INC. | UT | Form D private offerings | CIK (EXACT) |
| Patent assignee | Recursion Pharmaceuticals, Inc. | UT | Patents (USPTO) | name and state |
| SEC filer | RECURSION PHARMACEUTICALS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Recursion Pharmaceuticals, Inc. | UT | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | RECURSION PHARMACEUTICALS INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), UT first:
- POLARITYTE, INC. UT
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
- GENETIC TECHNOLOGIES LTD C3
- MESOBLAST LTD C3
- Ablynx NV C9
- SANGAMO THERAPEUTICS, INC CA
In other datasets, the same topic (Health) in UT:
- Nonprofit: 19 HOPE AND HEALING (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health